Results · Apr-Jun 2026 · filed 10 Aug 2026
Jubilant Pharmova Q1 FY27 results
Sales grew 17% to ₹2,229 crore from ₹1,901 crore in Apr-Jun 2025.
Operating profit fell 14% to ₹248 crore, an operating margin of 11.1% (down 4.1 points from a year ago).
Net profit fell 45% to ₹56.4 crore from ₹103 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −3%, net profit −53%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 2,229 | 1,901 | +17% |
| Operating profit (EBITDA) | 248.0 | 289.6 | −14% |
| Operating margin | 11.1% | 15.2% | −4.1 pts |
| Net profit | 56.4 | 102.5 | −45% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 11 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 10 Aug 2026Un-Audited Standalone & Consolidated Financial Results For The Quarter Ended June 30, 2026
- 10 Aug 2026Board Meeting Outcome for Meeting Held On August 10, 2026
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.